{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'imputation approach is to incorporate a representative random sample in place of the missing', 'data such that unbiased estimation and valid statistical inferences (ie, confidence intervals and', 'hypothesis testing) can be made.', 'Details with respect to the construction of the CMH test statistic, multiple imputation procedure', 'and the terminal analysis method for combining the multiple imputation results, as well as all', 'supportive sensitivity and subgroup analyses involving the stratums for the primary endpoint will', 'be specified in the SAP.', '9.6.2.', 'Secondary and Exploratory Efficacy Enppoints', 'For continuous endpoints at Week 16, an analysis of covariance (ANCOVA) model with', 'treatment and randomization strata as fixed effects and corresponding baseline value as a', 'continuous covariate will be employed. Missing data will be addressed using multiple', 'imputation. The adjusted means and standard errors will be reported for each of the treatment', 'group using the ANCOVA model, as well as the estimated treatment effect (ie, difference in the', 'adjusted treatment means, their standard errors, and 95% confidence intervals). In addition,', 'descriptive statistics will be provided based upon the observed data which will not address', 'missing data. Details regarding the methods of estimation to be performed at Weeks 32 and 52', 'will be provided in the statistical analysis plan (SAP).', 'For discrete endpoints, the CMH estimation method stratified by the randomization strata for', 'assessing the difference in proportion between the treatment groups will be conducted. The', 'weights in the CMH estimation method will be same as those used in the primary endpoint', 'analysis. The adjusted difference in the proportions between the treatment groups, their standard', 'errors, and corresponding 95% confidence intervals will be reported. Missing data will be', 'addressed through multiple imputation similar to that of the primary endpoint analysis. In', 'addition, descriptive statistics involving the sample size, the number of responders, and', 'proportion of responders will be summarized by treatment group. Details regarding the methods', 'of estimation to be performed at Weeks 32 and 52 will be provided in the SAP.', '9.6.3.', 'Photography', 'Photographs will be collected only at selected sites in subjects who consent and will be', 'considered as supportive evidence of efficacy. Descriptive summary of photography will be', 'addressed in the SAP and included in the clinical study report.', 'Photographs will be taken of all effected manifestations of plaque psoriasis at Weeks 0, 16, 32,', 'and 52.', 'Subjects must sign a separate consent form specific to Photography at Visit 1 (Screening Visit).', 'Confidential and Proprietary', '48', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '9.6.5.', 'Multiplicity Adjustment', 'There will be no multiplicity adjustment. Only the primary endpoint analysis will be used to', 'declare a statistical significance.', '9.7.', 'Safety Analysis', 'The safety analyses will be performed using the safety population as defined in Section 9.2,', 'defined as all subjects who are randomized and receive at least one dose of investigational', 'product. Safety will be assessed by clinical review of all relevant parameters including treatment-', 'emergent adverse events (TEAEs), laboratory tests, and vital signs; no inferential testing for', 'statistical significance will be performed. Data from safety assessments will be summarized', 'descriptively for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Exposure', 'Period when subjects receive apremilast treatment. For safety analyses in the Placebo-controlled', 'Phase, baseline will be relative to the first dose date following randomization at Week 0. For', 'safety analyses in Apremilast Exposure Period, baseline will be relative to the first apremilast', 'dose date at Week 0 for subjects initially randomized to apremilast or Week 16 for subjects', 'initially randomized to placebo and switched to apremilast in the Apremilast Extension Phase', '(Weeks 16-52).', 'Adverse events will be classified using the Medical Dictionary for Regulatory Activities', '(MedDRA) classification system. Adverse events will be tabulated by study phase (Double-blind', 'Placebo-controlled Phase or apremilast Exposure Phase). All treatment-emergent adverse events', '(AEs) will be summarized by system organ class, preferred term, severity, and relationship to IP.', 'Adverse events leading to death or to discontinuation from treatment and serious AEs will also', 'be summarized and listed separately.', 'Laboratory data will be summarized using shift tables showing the number of subjects with low,', 'normal, and high values based on the normal ranges, pretreatment versus post-treatment.', 'Vital sign measurements, including weight, will be summarized by visit descriptively (count,', 'mean, median, standard deviation, and range). In addition, shift tables showing the number of', 'subjects with values below, within and above the normal reference ranges pretreatment versus', 'post-treatment will be provided.', 'The changes and percent changes in body weight will be summarized by visit. In addition, the', 'changes by baseline body mass index (BMI; (< 18.5, 18.5 to < 25, 25 to < 30, 30 to < 35, 35 to', '< 40, > 40 kg/m\u00b2) will be explored.', '9.8.', 'Interim Analysis', 'No interim analysis is planned for this study.', '9.9.', 'Other Topics', '9.9.1.', 'Investigational Product Compliance (Tablets)', 'Investigational product record information will be summarized. Overall compliance will be', 'estimated by the proportion of subjects who take between 75% and 120% of the intended', 'quantity of IP.', 'Confidential and Proprietary', '49', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '9.9.2.', 'Concomitant Therapy', 'All concomitant treatments documented during the study period will be summarized in frequency', 'tabulations. The Anatomical Therapeutic Chemical (ATC) coding scheme of the World Health', 'Organization (WHO) will be used to group medications into relevant categories for these', 'tabulations. Separate data summaries of background medications will be provided.', '9.9.3.', 'Steering Committee', 'The conduct of this trial will be overseen by a steering committee (SC), presided over by the', 'coordinating Principal Investigator. The SC will serve in an advisory capacity to the Sponsor.', 'Operational details for the SC will be detailed in a separate SC charter.', 'Confidential and Proprietary', '50', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}